A Evaluation of Systematic Intensive Therapy Using CGM/FGM in Clinical Diabetes Care
- Conditions
- Type1diabetes
- Interventions
- Other: systematic intensive therapy
- Registration Number
- NCT03474393
- Lead Sponsor
- Vastra Gotaland Region
- Brief Summary
This study aims to analyse if intensive systematic treatment via internet and telephone during 4 months improved HbA1c for persons with type 1 diabetes which are already treated with CGM or FGM, and if the effect continuous for 1-2 years after the intervention stops. Time in Hypoglycaemia, treatment satisfaction, Diabetes distress and hypoglycaemia fear will even be analysed.
A randomised, non-blinded, multi-centre, clinical study for persons with type 1 diabetes and hbA1c ≥ 58mmol/mol and treated with CGM or FGM.
The control group continuous its normal diabetes care with study visits at randomisation, 10, 18, 32, and 52 weeks for HbA1c and to fill in questionnaires.
The intervention group will have contact with the study team on a weekly basis, when mean blood glucose levels the previous week are elevated. They will receive help with analysing data and advice on how to improve their glucose values. They will even meet the study team at randomisation, 10, 18, 32, and 52 weeks for HbA1c and to fill in questionnaires.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 117
- Informed consent obtained before trial-related activities (i.e., any activity that would not have been performed during routine patient management)
- Clinical diagnosis of Type 1 diabetes
- Adult patients over 18 years of age
- HbA1c ≥ 58 mmol/mol
- Currently using CGM or FGM
- To have a possibility to download and share FGM/CGM data
- Type 2 diabetes
- Diabetes duration <1 year
- Long-term Systemic glucocorticoid treatment during the last 3 months
- Planned or changed treatment the last 3 months regarding MDI vs. Insulin pump or added or stopped CGM or FGM therapy
- Current or planned pregnancy or breastfeeding during the next 12 months
- Planned move during the next 12 months making it not possible to participate in study activities
- Other reason determined by the investigator not being appropriate for participation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Systematic intensive therapy systematic intensive therapy Intensive Internet and telephone contact for 4 months and Control visits
- Primary Outcome Measures
Name Time Method Change in HbA1c from baseline to 18 weeks Change in HbA1c from baseline to week 18
- Secondary Outcome Measures
Name Time Method Time in Range from baseline to 18 weeks Change in Time in Range (4-10mmol/l) and from Baseline to week 18
Mean glucose levels from baseline to 18 weeks Change in mean glucose levels from baseline to 18
HbA1c at week 52 From baseline to 52 weeks Change in HbA1c from baseline to week 52
HbA1c at week 32 From baseline to 18 weeks Change in HbA1c from baseline to week 32
Time above range from baseline to 18 weeks Change in time above range (glucose values above 10mmol/L) from baseline to 18 weeks
Trial Locations
- Locations (1)
NU-Hosptial Group
🇸🇪Uddevalla, Sweden